AbCellera Biologics (ABCL) Total Liabilities (2020 - 2026)
AbCellera Biologics' (ABCL) quarterly Total Liabilities came in at $369.0 million in Q1 2026, up 14.88% YoY from $321.2 million in Q1 2025, and down 5.39% on a QoQ basis from $390.0 million in Q4 2025.
AbCellera Biologics (ABCL) Total Liabilities (2020 - 2026) Analysis & Trends
AbCellera Biologics (ABCL) has 7 years of Total Liabilities data on file, last reported at $369.0 million in Q1 2026.
- Quarterly Total Liabilities rose 14.88% year-over-year to $369.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $369.0 million (up 14.88% YoY) and the FY2025 annual result came in at $390.0 million, up 28.11% from the prior year.
- Total Liabilities retreated to $369.0 million in Q1 2026, from $390.0 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $395.0 million in Q2 2025 to a low of $289.4 million in Q1 2023.
- A 5-year average of $340.8 million and a median of $333.2 million in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities jumped 124.49% — and 2023, when it retreated 24.78%.
- Tracing ABCL's Total Liabilities over 5 years: stood at $307.6 million in 2022, then advanced by 9.15% to $335.8 million in 2023, then decreased by 9.32% to $304.5 million in 2024, then grew by 28.11% to $390.0 million in 2025, then dropped by 5.39% to $369.0 million in 2026.
- The last three Total Liabilities figures came in at $369.0 million (Q1 2026), $390.0 million (Q4 2025), and $392.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | AbCellera Biologics | 3.49 Bn | 3.49 Bn | - | 411.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 411.56 Mn |
| Mar 31, 2026 | 369.03 Mn |
| Dec 31, 2025 | 390.05 Mn |
| Sep 30, 2025 | 391.95 Mn |
| Jun 30, 2025 | 394.99 Mn |
| Mar 31, 2025 | 321.23 Mn |
| Dec 31, 2024 | 304.47 Mn |
| Sep 30, 2024 | 314.73 Mn |
| Jun 30, 2024 | 301.51 Mn |
| Mar 31, 2024 | 333.18 Mn |
| Dec 31, 2023 | 335.78 Mn |
| Sep 30, 2023 | 329.42 Mn |
| Jun 30, 2023 | 342.34 Mn |
| Mar 31, 2023 | 289.42 Mn |
| Dec 31, 2022 | 307.63 Mn |
| Sep 30, 2022 | 302.24 Mn |
| Jun 30, 2022 | 380.93 Mn |
| Mar 31, 2022 | 384.78 Mn |
| Dec 31, 2021 | 292.84 Mn |
| Sep 30, 2021 | 219.34 Mn |